[go: up one dir, main page]

DK1368060T3 - HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme - Google Patents

HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme

Info

Publication number
DK1368060T3
DK1368060T3 DK02717057.0T DK02717057T DK1368060T3 DK 1368060 T3 DK1368060 T3 DK 1368060T3 DK 02717057 T DK02717057 T DK 02717057T DK 1368060 T3 DK1368060 T3 DK 1368060T3
Authority
DK
Denmark
Prior art keywords
treatment
antagonists
vascular disease
protein inhibitors
hmgb1 protein
Prior art date
Application number
DK02717057.0T
Other languages
English (en)
Inventor
Marco E Bianchi
Tiziana Bonaldi
Paola Scaffidi
Susanne Mueller
Bernard Degryse
Original Assignee
Bio3 Res S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio3 Res S R L filed Critical Bio3 Res S R L
Application granted granted Critical
Publication of DK1368060T3 publication Critical patent/DK1368060T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02717057.0T 2001-03-16 2002-03-12 HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme DK1368060T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000562A ITMI20010562A1 (it) 2001-03-16 2001-03-16 Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
PCT/IT2002/000153 WO2002074337A1 (en) 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases

Publications (1)

Publication Number Publication Date
DK1368060T3 true DK1368060T3 (da) 2010-08-30

Family

ID=11447291

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02717057.0T DK1368060T3 (da) 2001-03-16 2002-03-12 HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme

Country Status (14)

Country Link
US (4) US7754217B2 (da)
EP (1) EP1368060B1 (da)
JP (1) JP4822654B2 (da)
CN (2) CN1537014B (da)
AT (1) ATE468137T1 (da)
AU (1) AU2002247977C1 (da)
CA (1) CA2439530C (da)
DE (1) DE60236413D1 (da)
DK (1) DK1368060T3 (da)
ES (1) ES2346408T3 (da)
IT (1) ITMI20010562A1 (da)
MX (1) MXPA03008364A (da)
PT (1) PT1368060E (da)
WO (1) WO2002074337A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
US20030060410A1 (en) * 2001-05-15 2003-03-27 North Shore Long Island Jewish Research Institute Use of HMG fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
ATE424416T1 (de) 2002-07-03 2009-03-15 San Raffaele Centro Fond Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
CA2512512A1 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of hmgb, hmgn, hmga proteins
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
DK1768677T3 (da) * 2004-07-02 2008-10-20 Creabilis Therapeutics Spa Nucleinsyrer til behandling af HMGB1-relaterede patologier
CA2574548A1 (en) 2004-07-20 2006-01-26 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 for wound healing
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
MX2007002557A (es) * 2004-09-03 2007-10-10 Creabilis Therapeutics Spa Uso de polipeptidos obtenidos a traves de mutaciones sistematicas de aminoacidos unicos de bloque-a humano y no humano de hmgb1 para prevenir y/o antagonizar las patologias inducidas por hmgb1.
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
AU2005333602B2 (en) 2004-10-22 2012-04-12 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
ITRM20050032A1 (it) * 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
PT1919979E (pt) 2005-08-25 2014-03-07 Creabilis Therapeutics Spa Polímeros conjugados de k-252a e seus derivados
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
JP2009517404A (ja) 2005-11-28 2009-04-30 メディミューン，エルエルシー Ｈｍｇｂ１および／またはｒａｇｅのアンタゴニストならびにその使用方法
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
PL2068935T3 (pl) 2006-09-15 2011-11-30 Creabilis Therapeutics S R L Polimerowe koniugaty BOX-A HMGB1 i warianty HMGB1
US8470325B2 (en) 2007-02-15 2013-06-25 Kagoshima University Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5660889B2 (ja) 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
EP2455469A4 (en) 2009-07-16 2013-03-13 Nec Software Ltd FOR BINDING TO HMGB1 ABLE NUCLEIC ACID MOLECULE AND USE THEREOF
JP5467313B2 (ja) 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
WO2011052668A1 (ja) 2009-10-28 2011-05-05 株式会社ジェノミックス 骨髄間葉系および/または多能性幹細胞の血中動員による組織再生促進剤
RU2013123796A (ru) 2010-10-30 2014-12-10 Исис Инновэйшн Лтд Способ лечения болезни дюпюитрена
CN114106139B (zh) 2011-04-26 2024-08-30 斯特姆里姆有限公司 用于诱导组织再生的肽及其应用
WO2012170740A2 (en) * 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
DK2949675T3 (da) 2013-01-28 2021-04-26 Evec Inc Humaniseret anti-hmgb1-antistof eller antigen-bindende fragment deraf
IL242807A0 (en) 2015-11-26 2016-04-21 Novamed Ltd Test facility
CN108367049A (zh) 2015-12-11 2018-08-03 海德堡吕布莱希特-卡尔斯大学 Pkm2调节剂和hmgb1的组合制剂
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
JPWO2019107566A1 (ja) 2017-12-01 2020-12-03 株式会社ステムリム 外胚葉性間葉系幹細胞およびその製造方法
WO2019107530A1 (ja) 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
EP4138878A4 (en) * 2020-04-22 2024-03-20 Chulalongkorn University A composition and a method of rejuvenating dna and preventing dna damage

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5470307A (en) * 1994-03-16 1995-11-28 Lindall; Arnold W. Catheter system for controllably releasing a therapeutic agent at a remote tissue site
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6398808B1 (en) 1999-06-15 2002-06-04 Scimed Life Systems, Inc. Localized delivery of genetic information from biostable materials
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
US20030060410A1 (en) * 2001-05-15 2003-03-27 North Shore Long Island Jewish Research Institute Use of HMG fragments as anti-inflammatory agents
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
CA2574548A1 (en) * 2004-07-20 2006-01-26 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 for wound healing
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof

Also Published As

Publication number Publication date
PT1368060E (pt) 2010-08-24
AU2002247977C1 (en) 2008-09-18
CA2439530A1 (en) 2002-09-26
ITMI20010562A1 (it) 2002-09-16
AU2002247977B8 (en) 2007-03-15
DE60236413D1 (de) 2010-07-01
US20040136979A1 (en) 2004-07-15
WO2002074337A8 (en) 2003-08-28
CN1537014B (zh) 2012-04-25
ES2346408T3 (es) 2010-10-15
US8058239B2 (en) 2011-11-15
AU2002247977A2 (en) 2004-02-26
HK1069316A1 (en) 2005-05-20
US20080171052A1 (en) 2008-07-17
WO2002074337A1 (en) 2002-09-26
ATE468137T1 (de) 2010-06-15
MXPA03008364A (es) 2004-11-12
EP1368060A1 (en) 2003-12-10
JP4822654B2 (ja) 2011-11-24
US20100297107A1 (en) 2010-11-25
CN101773669A (zh) 2010-07-14
AU2002247977A1 (en) 2002-10-03
CN1537014A (zh) 2004-10-13
US20100172896A1 (en) 2010-07-08
CA2439530C (en) 2016-11-08
US7754217B2 (en) 2010-07-13
AU2002247977B2 (en) 2006-12-14
JP2004523579A (ja) 2004-08-05
EP1368060B1 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
ATE315938T1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
BG66080B1 (bg) Заместени тиоацетамиди
DK1411064T3 (da) Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
SE0302304D0 (sv) Novel compounds
EA200400399A1 (ru) Способы лечения легочных заболеваний
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
TR200200278T2 (tr) Kalsilitik bileşimler
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
ATE353693T1 (de) Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
NO20005548L (no) Mykobakterieinhibitorer
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях